Statements (34)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
MEK inhibitor |
| gptkbp:approvalYear |
2018
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01EE38
|
| gptkbp:brand |
gptkb:Mektovi
|
| gptkbp:CASNumber |
606143-52-6
|
| gptkbp:chemicalClass |
pyridopyrimidine derivative
|
| gptkbp:combines |
gptkb:encorafenib
|
| gptkbp:contraindication |
pregnancy
lactation |
| gptkbp:developedBy |
gptkb:Array_BioPharma
|
| gptkbp:hasMolecularFormula |
C17H15BrF2N4O3
|
| https://www.w3.org/2000/01/rdf-schema#label |
binimetinib
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits MEK1 and MEK2
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL1873475
gptkb:DB11707 46216347 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting diarrhea edema fatigue rash increased creatine phosphokinase |
| gptkbp:target |
gptkb:MAPK/ERK_pathway
|
| gptkbp:UNII |
Q1J8A4N5FD
|
| gptkbp:usedFor |
treatment of melanoma
treatment of non-small cell lung cancer |
| gptkbp:bfsParent |
gptkb:Array_BioPharma
|
| gptkbp:bfsLayer |
5
|